Intrinsic value of Balchem - BCPC

Previous Close

$116.06

  Intrinsic Value

$37.63

stock screener

  Rating & Target

str. sell

-68%

Previous close

$116.06

 
Intrinsic value

$37.63

 
Up/down potential

-68%

 
Rating

str. sell

We calculate the intrinsic value of BCPC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 3.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  11.30
  10.67
  10.10
  9.59
  9.13
  8.72
  8.35
  8.01
  7.71
  7.44
  7.20
  6.98
  6.78
  6.60
  6.44
  6.30
  6.17
  6.05
  5.95
  5.85
  5.77
  5.69
  5.62
  5.56
  5.50
  5.45
  5.41
  5.37
  5.33
  5.30
Revenue, $m
  662
  733
  807
  884
  965
  1,049
  1,136
  1,228
  1,322
  1,421
  1,523
  1,629
  1,740
  1,854
  1,974
  2,098
  2,227
  2,362
  2,503
  2,649
  2,802
  2,961
  3,128
  3,302
  3,483
  3,673
  3,872
  4,080
  4,297
  4,525
Variable operating expenses, $m
  546
  599
  653
  710
  770
  832
  897
  964
  1,034
  1,107
  1,126
  1,204
  1,286
  1,371
  1,459
  1,551
  1,647
  1,746
  1,850
  1,958
  2,071
  2,189
  2,312
  2,441
  2,575
  2,715
  2,862
  3,016
  3,177
  3,345
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  546
  599
  653
  710
  770
  832
  897
  964
  1,034
  1,107
  1,126
  1,204
  1,286
  1,371
  1,459
  1,551
  1,647
  1,746
  1,850
  1,958
  2,071
  2,189
  2,312
  2,441
  2,575
  2,715
  2,862
  3,016
  3,177
  3,345
Operating income, $m
  116
  134
  153
  174
  195
  217
  239
  263
  288
  313
  397
  425
  454
  483
  515
  547
  581
  616
  653
  691
  731
  772
  816
  861
  908
  958
  1,010
  1,064
  1,120
  1,180
EBITDA, $m
  203
  225
  248
  271
  296
  322
  349
  377
  406
  436
  467
  500
  534
  569
  606
  644
  684
  725
  768
  813
  860
  909
  960
  1,013
  1,069
  1,127
  1,188
  1,252
  1,319
  1,389
Interest expense (income), $m
  7
  12
  14
  16
  19
  21
  23
  26
  29
  32
  35
  38
  41
  44
  48
  52
  55
  59
  63
  68
  72
  77
  81
  86
  92
  97
  103
  109
  115
  122
  128
Earnings before tax, $m
  104
  120
  137
  155
  174
  193
  213
  234
  256
  279
  359
  384
  409
  436
  463
  492
  522
  553
  585
  619
  654
  691
  729
  769
  811
  855
  901
  949
  999
  1,051
Tax expense, $m
  28
  32
  37
  42
  47
  52
  58
  63
  69
  75
  97
  104
  110
  118
  125
  133
  141
  149
  158
  167
  177
  186
  197
  208
  219
  231
  243
  256
  270
  284
Net income, $m
  76
  88
  100
  113
  127
  141
  156
  171
  187
  203
  262
  280
  299
  318
  338
  359
  381
  403
  427
  452
  477
  504
  532
  562
  592
  624
  657
  692
  729
  767

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,073
  1,187
  1,307
  1,433
  1,564
  1,700
  1,842
  1,990
  2,143
  2,302
  2,468
  2,640
  2,819
  3,005
  3,199
  3,400
  3,610
  3,829
  4,056
  4,294
  4,541
  4,799
  5,069
  5,351
  5,645
  5,953
  6,275
  6,612
  6,964
  7,333
Adjusted assets (=assets-cash), $m
  1,073
  1,187
  1,307
  1,433
  1,564
  1,700
  1,842
  1,990
  2,143
  2,302
  2,468
  2,640
  2,819
  3,005
  3,199
  3,400
  3,610
  3,829
  4,056
  4,294
  4,541
  4,799
  5,069
  5,351
  5,645
  5,953
  6,275
  6,612
  6,964
  7,333
Revenue / Adjusted assets
  0.617
  0.618
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
  0.617
Average production assets, $m
  520
  575
  633
  694
  757
  823
  892
  964
  1,038
  1,115
  1,195
  1,279
  1,366
  1,456
  1,549
  1,647
  1,749
  1,854
  1,965
  2,080
  2,199
  2,325
  2,455
  2,592
  2,734
  2,883
  3,039
  3,202
  3,373
  3,552
Working capital, $m
  95
  105
  116
  127
  139
  151
  164
  177
  190
  205
  219
  235
  250
  267
  284
  302
  321
  340
  360
  381
  403
  426
  450
  475
  502
  529
  558
  587
  619
  652
Total debt, $m
  258
  300
  343
  388
  435
  484
  535
  588
  644
  701
  761
  823
  887
  954
  1,024
  1,096
  1,172
  1,251
  1,332
  1,418
  1,507
  1,600
  1,697
  1,799
  1,905
  2,015
  2,131
  2,252
  2,379
  2,512
Total liabilities, $m
  386
  427
  471
  516
  563
  612
  663
  716
  771
  829
  889
  951
  1,015
  1,082
  1,152
  1,224
  1,300
  1,378
  1,460
  1,546
  1,635
  1,728
  1,825
  1,926
  2,032
  2,143
  2,259
  2,380
  2,507
  2,640
Total equity, $m
  687
  760
  837
  917
  1,001
  1,088
  1,179
  1,273
  1,371
  1,474
  1,580
  1,690
  1,804
  1,923
  2,047
  2,176
  2,311
  2,450
  2,596
  2,748
  2,906
  3,072
  3,244
  3,425
  3,613
  3,810
  4,016
  4,232
  4,457
  4,693
Total liabilities and equity, $m
  1,073
  1,187
  1,308
  1,433
  1,564
  1,700
  1,842
  1,989
  2,142
  2,303
  2,469
  2,641
  2,819
  3,005
  3,199
  3,400
  3,611
  3,828
  4,056
  4,294
  4,541
  4,800
  5,069
  5,351
  5,645
  5,953
  6,275
  6,612
  6,964
  7,333
Debt-to-equity ratio
  0.380
  0.390
  0.410
  0.420
  0.430
  0.450
  0.450
  0.460
  0.470
  0.480
  0.480
  0.490
  0.490
  0.500
  0.500
  0.500
  0.510
  0.510
  0.510
  0.520
  0.520
  0.520
  0.520
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.540
Adjusted equity ratio
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640
  0.640

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  76
  88
  100
  113
  127
  141
  156
  171
  187
  203
  262
  280
  299
  318
  338
  359
  381
  403
  427
  452
  477
  504
  532
  562
  592
  624
  657
  692
  729
  767
Depreciation, amort., depletion, $m
  88
  91
  94
  98
  101
  105
  109
  114
  118
  123
  70
  75
  80
  86
  91
  97
  103
  109
  116
  122
  129
  137
  144
  152
  161
  170
  179
  188
  198
  209
Funds from operations, $m
  163
  178
  194
  211
  228
  246
  265
  285
  305
  326
  333
  355
  379
  404
  429
  456
  484
  513
  543
  574
  607
  641
  677
  714
  753
  794
  836
  881
  928
  976
Change in working capital, $m
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  15
  16
  17
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
Cash from operations, $m
  154
  168
  184
  200
  217
  234
  252
  271
  291
  312
  318
  340
  363
  387
  412
  438
  465
  493
  522
  553
  585
  618
  653
  689
  727
  766
  808
  851
  896
  944
Maintenance CAPEX, $m
  -27
  -31
  -34
  -37
  -41
  -45
  -48
  -52
  -57
  -61
  -66
  -70
  -75
  -80
  -86
  -91
  -97
  -103
  -109
  -116
  -122
  -129
  -137
  -144
  -152
  -161
  -170
  -179
  -188
  -198
New CAPEX, $m
  -53
  -55
  -58
  -61
  -63
  -66
  -69
  -71
  -74
  -77
  -80
  -83
  -87
  -90
  -94
  -98
  -102
  -106
  -110
  -115
  -120
  -125
  -131
  -136
  -143
  -149
  -156
  -163
  -171
  -179
Cash from investing activities, $m
  -80
  -86
  -92
  -98
  -104
  -111
  -117
  -123
  -131
  -138
  -146
  -153
  -162
  -170
  -180
  -189
  -199
  -209
  -219
  -231
  -242
  -254
  -268
  -280
  -295
  -310
  -326
  -342
  -359
  -377
Free cash flow, $m
  73
  82
  92
  102
  112
  124
  135
  148
  160
  174
  172
  186
  201
  217
  233
  249
  267
  284
  303
  322
  343
  364
  385
  408
  432
  456
  482
  509
  537
  566
Issuance/(repayment) of debt, $m
  40
  41
  43
  45
  47
  49
  51
  53
  55
  57
  60
  62
  64
  67
  70
  73
  75
  79
  82
  85
  89
  93
  97
  101
  106
  111
  116
  121
  127
  133
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  40
  41
  43
  45
  47
  49
  51
  53
  55
  57
  60
  62
  64
  67
  70
  73
  75
  79
  82
  85
  89
  93
  97
  101
  106
  111
  116
  121
  127
  133
Total cash flow (excl. dividends), $m
  113
  123
  135
  147
  160
  173
  186
  201
  216
  231
  232
  248
  266
  284
  302
  322
  342
  363
  385
  408
  432
  457
  482
  509
  538
  567
  598
  630
  664
  699
Retained Cash Flow (-), $m
  -70
  -73
  -77
  -80
  -84
  -87
  -91
  -94
  -98
  -102
  -106
  -110
  -115
  -119
  -124
  -129
  -134
  -140
  -146
  -152
  -158
  -165
  -173
  -180
  -188
  -197
  -206
  -216
  -226
  -236
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  43
  50
  58
  67
  76
  85
  96
  106
  117
  129
  126
  138
  151
  164
  178
  193
  208
  223
  239
  256
  273
  291
  310
  329
  349
  370
  392
  415
  438
  463
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  41
  46
  51
  55
  59
  62
  65
  66
  67
  68
  60
  59
  57
  55
  52
  49
  45
  41
  37
  33
  28
  24
  20
  17
  14
  11
  8
  6
  5
  3
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Balchem Corporation is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization and industrial markets. The Company operates in four segments: Human Nutrition & Health, Animal Nutrition & Health, Specialty Products and Industrial Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry, providing solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems and cereal systems. The Animal Nutrition & Health segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment sells ethylene oxide as a sterilant gas primarily for use in the healthcare industry. The Industrial Products segment includes the manufacture and sale of methylamines.

FINANCIAL RATIOS  of  Balchem (BCPC)

Valuation Ratios
P/E Ratio 65.8
Price to Sales 6.7
Price to Book 7.1
Price to Tangible Book
Price to Cash Flow 34.1
Price to Free Cash Flow 43.9
Growth Rates
Sales Growth Rate 0.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -42.9%
Cap. Spend. - 3 Yr. Gr. Rate 24.6%
Financial Strength
Quick Ratio 1
Current Ratio 0
LT Debt to Equity 47%
Total Debt to Equity 53.7%
Interest Coverage 13
Management Effectiveness
Return On Assets 6.6%
Ret/ On Assets - 3 Yr. Avg. 7.7%
Return On Total Capital 7.2%
Ret/ On T. Cap. - 3 Yr. Avg. 8.4%
Return On Equity 11.4%
Return On Equity - 3 Yr. Avg. 13.4%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 32.7%
Gross Margin - 3 Yr. Avg. 29.9%
EBITDA Margin 24.6%
EBITDA Margin - 3 Yr. Avg. 23.2%
Operating Margin 16.5%
Oper. Margin - 3 Yr. Avg. 16.2%
Pre-Tax Margin 15%
Pre-Tax Margin - 3 Yr. Avg. 15%
Net Profit Margin 10.1%
Net Profit Margin - 3 Yr. Avg. 10.3%
Effective Tax Rate 32.5%
Eff/ Tax Rate - 3 Yr. Avg. 31.6%
Payout Ratio 19.6%

BCPC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BCPC stock intrinsic value calculation we used $594.79 million for the last fiscal year's total revenue generated by Balchem. The default revenue input number comes from 0001 income statement of Balchem. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BCPC stock valuation model: a) initial revenue growth rate of 11.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BCPC is calculated based on our internal credit rating of Balchem, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Balchem.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BCPC stock the variable cost ratio is equal to 83.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BCPC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Balchem.

Corporate tax rate of 27% is the nominal tax rate for Balchem. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BCPC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BCPC are equal to 78.5%.

Life of production assets of 17 years is the average useful life of capital assets used in Balchem operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BCPC is equal to 14.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $616.881 million for Balchem - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 32.211 million for Balchem is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Balchem at the current share price and the inputted number of shares is $3.7 billion.

RELATED COMPANIES Price Int.Val. Rating
SXT Sensient Techn 77.06 87.51  buy
IPHS Innophos Holdi 45.74 41.28  hold
MMM 3M 216.33 232.48  hold
ACET Aceto 3.04 26.63  str.buy
EMN Eastman Chemic 99.88 133.47  buy

COMPANY NEWS

▶ Balchem Corporation Acquires Bioscreen Technologies, S.r.l.   [Aug-29-18 04:15PM  GlobeNewswire]
▶ Growth Streak Continues for Balchem Corporation   [Aug-06-18 09:18AM  Motley Fool]
▶ Balchem Corporation to Host Earnings Call   [Aug-03-18 09:00AM  ACCESSWIRE]
▶ Blachem: 2Q Earnings Snapshot   [07:35AM  Associated Press]
▶ Is Balchem Corporation (NASDAQ:BCPC) Undervalued?   [Jun-24-18 09:56AM  Simply Wall St.]
▶ Balchem Reports Strong Growth to Begin 2018   [May-09-18 01:15PM  Motley Fool]
▶ Blachem: 1Q Earnings Snapshot   [May-04-18 07:35AM  Associated Press]
▶ Health and Nutrition Growth Drives Balchem Corporation   [Mar-06-18 07:05AM  Motley Fool]
▶ Balchem Corporation to Host Earnings Call   [Feb-27-18 09:15AM  ACCESSWIRE]
▶ ETFs with exposure to Balchem Corp. : December 29, 2017   [Dec-29-17 11:33AM  Capital Cube]
▶ Balchem Corporation Announces Dividend   [Dec-15-17 09:00AM  GlobeNewswire]
▶ ETFs with exposure to Balchem Corp. : December 7, 2017   [Dec-07-17 01:00PM  Capital Cube]
▶ Industrial Sales Boost Balchem Corporation's Bottom Line   [Nov-14-17 07:31AM  Motley Fool]
▶ Blachem posts 3Q profit   [07:29AM  Associated Press]
▶ ETFs with exposure to Balchem Corp. : October 26, 2017   [Oct-26-17 10:20AM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : October 10, 2017   [Oct-10-17 11:02AM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : September 26, 2017   [Sep-26-17 10:43AM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : September 12, 2017   [Sep-11-17 09:32PM  Capital Cube]
▶ Blachem posts 2Q profit   [Aug-04-17 10:21PM  Associated Press]
▶ ETFs with exposure to Balchem Corp. : July 4, 2017   [Jul-04-17 02:38PM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : June 22, 2017   [Jun-22-17 03:25PM  Capital Cube]
▶ Balchem Reports Record Earnings in First Quarter   [May-09-17 02:13PM  Motley Fool]
▶ Blachem posts 1Q profit   [10:11AM  Associated Press]
▶ Balchem Corp. Value Analysis (NASDAQ:BCPC) : May 3, 2017   [May-03-17 04:35PM  Capital Cube]
▶ ETFs with exposure to Balchem Corp. : April 19, 2017   [Apr-19-17 02:12PM  Capital Cube]
▶ Health Products Drive Balchem Corporation's Growth   [Mar-01-17 03:43PM  Motley Fool]
▶ Blachem posts 4Q profit   [08:23AM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.